Tullaga, Terenesa B.
HRN: 12-79-44 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/26/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/26/2022
08/02/2022
IV
500mg
Q8
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes